Actively Recruiting
Phase II Study of Recombinant Human IL-21-Expressing Oncolytic Vaccinia Virus Injection hV01 for Treating Advanced Pancreatic Cancer
Led by Hangzhou Converd Co., Ltd. · Updated on 2026-02-27
12
Participants Needed
1
Research Sites
9 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of recombinant human IL-21-expressing oncolytic vaccinia virus injection hV01 in patients with advanced pancreatic cancer who have not responded to standard treatments. The study aims to assess both the preliminary effectiveness and safety of this new treatment. This is an exploratory phase II clinical trial led by Hangzhou Converd Co., Ltd. Participants will receive intratumoral injections of hV01 at a dose of 8.0 x 108 PFU on day 1 and day 15 of each 28-day treatment cycle. Efficacy will be evaluated on day 28 and every 28 days thereafter, with safety observations throughout the treatment. The study uses a single-arm, open-label design at a single site. During the study, participants will undergo assessments to monitor tumor response, including overall response rate, disease control rate, and duration of response, with follow-up up to two years after treatment ends. Additional outcomes include progression-free survival, overall survival, and evaluation of adverse events up to 28 days after dosing. Laboratory tests, imaging, and clinical evaluations will be conducted regularly to track safety and effectiveness.
CONDITIONS
Brief Title
Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer
Research Team
M
Meng Li
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here